Our meta-analysis study with a large sample size of 2,437 psoriasis patients using IL-17 inhibitors and 4,669 psoriasis patients using non-biologics strongly support that the use of IL-17 inhibitors in patients with psoriasis does not increase the risk of SARS-CoV-2 infection or worsen the course of COVID-19. Here, IL17A is linked to psoriasis.